Posters réalisés en 2017

EURODURG 2017, European Drug Utilisation Research Group Conference, Glasgow, UK, 15-17 November 2017. Manon Belhassen, Marjorie Bérard, Alexandra L. Dima, Marine Ginoux, Eric Van Ganse. “How often do asthma patients claim prescribed therapy?
EURODURG 2017, European Drug Utilisation Research Group Conference, Glasgow, UK, 15-17 November 2017. E. Van Ganse, N. Texier, L. Laforest, A. L. Dima, F. Jacoud, S. Schück, M. Ferrer, O. Garin, M. de Bruin, and the ASTROLAB GROUP. “LABA safety in actual medical practice: results from the longitudinal, time-dependent analyses of the ASTROLAB data
EURODURG 2017, European Drug Utilisation Research Group Conference, Glasgow, UK, 15-17 November 2017. Manon Belhassen, Alexandra L. Dima, Maëva Nolin, Nathalie Texier, Montse Ferrer, Marijn de Bruin, Eric Van Ganse and the ASTROLAB group. “Therapeutic ratios predict asthma control in the ASTROLAB cohort
ERS 2017, 27th Annual Congress of the European Respiratory Society, Milan, Italy, 9-13 September 2017. Manon Belhassen, Alexandra L. Dima, Maëva Nolin, Nathalie Texier, Montse Ferrer, Marijn de Bruin, Eric Van Ganse and the ASTROLAB group. “Therapeutic ratios predict asthma control in the ASTROLAB cohort
ERS 2017, 27th Annual Congress of the European Respiratory Society, Milan, Italy, 9-13 September 2017. Manon Belhassen, Marjorie Bérard, Alexandra L. Dima, Marine Ginoux, Eric Van Ganse. “How often do asthma patients claim prescribed therapy?
ICPE 2017, 33rd International Conference on PharmacoEpidemiology, Montreal, Canada, 26-30 August 2017. Manon Belhassen, Alexandra L. Dima, Maëva Nolin, Nathalie Texier, Montse Ferrer, Marijn de Bruin, Eric Van Ganse and the ASTROLAB group. “Therapeutic ratios predict asthma control in the ASTROLAB cohort
ICPE 2017, 33rd International Conference on PharmacoEpidemiology, Montreal, Canada, 26-30 August 2017. Manon Belhassen, Marjorie Bérard, Alexandra L. Dima, Marine Ginoux, Eric Van Ganse. “How often do asthma patients claim prescribed therapy?
ICPE 2017, 33rd International Conference on PharmacoEpidemiology, Montreal, Canada, 26-30 August 2017. M. Belhassen, F. Tubach, C. Hudry, M.-C. Woronoff, L. Levy-Bachelot, L. Lamezec, E. Van Ganse, B. Fautrel. “Impact of non-persistence to subcutaneous TNF-Alpha inhibitors on medical resource utilization and costs
ICPE 2017, 33rd International Conference on PharmacoEpidemiology, Montreal, Canada, 26-30 August 2017. B. Fautrel, M. Belhassen, C. Hudry, M.-C. Woronoff, N. Gouyette, A. Clément, E. Van Ganse, F. Tubach. “Determinants of 12-month persistence in rheumatoid arthritis patients initiating subcutaneous TNF-Alpha inhibitors
ICPE 2017, 33rd International Conference on PharmacoEpidemiology, Montreal, Canada, 26-30 August 2017. B. Fautrel, M. Belhassen, C. Hudry, M.-C. Woronoff, N. Gouyette, A. Clément, E. Van Ganse, F. Tubach. “Determinants of 12-month persistence in ankylosing spondilitis patients initiating subcutaneous TNF-Alpha inhibitors
ICPE 2017, 33rd International Conference on PharmacoEpidemiology, Montreal, Canada, 26-30 August 2017. B. Fautrel, M. Belhassen, C. Hudry, M.-C. Woronoff, N. Gouyette, A. Clément, E. Van Ganse, F. Tubach. “Determinants of 12-month persistence in psoriatic arthritis patients initiating subcutaneous TNF-Alpha inhibitors
EULAR 2017, Annual European Congress of Rheumatology, Madrid, Spain, 14-17 June 2017. M. Belhassen, F. Tubach, C. Hudry, M.-C. Woronoff, L. Levy-Bachelot, L. Lamezec, E. Van Ganse, B. Fautrel. “Impact of non-persistence to subcutaneous TNF-Alpha inhibitors on medical resource utilization and costs
EULAR 2017, Annual European Congress of Rheumatology, Madrid, Spain, 14-17 June 2017. M. Belhassen, F. Tubach, C. Hudry, M.-C. Woronoff, L. Levy-Bachelot, L. Lamezec, E. Van Ganse, B. Fautrel. “Determinants of 12-month persistence in ankylosing spondilitis patients initiating subcutaneous TNF-Alpha inhibitors
EULAR 2017, Annual European Congress of Rheumatology, Madrid, Spain, 14-17 June 2017. M. Belhassen, F. Tubach, C. Hudry, M.-C. Woronoff, L. Levy-Bachelot, L. Lamezec, E. Van Ganse, B. Fautrel. “Determinants of 12-month persistence in psoriatic arthritis patients initiating subcutaneous TNF-Alpha inhibitors
EULAR 2017, Annual European Congress of Rheumatology, Madrid, Spain, 14-17 June 2017. M. Belhassen, F. Tubach, C. Hudry, M.-C. Woronoff, L. Levy-Bachelot, L. Lamezec, E. Van Ganse, B. Fautrel. “Determinants of 12-month persistence in rheumatoid arthritis patients initiating subcutaneous TNF-Alpha inhibitors
9ème Colloque Données de santé en vie réelle, Paris, France, 13 June 2017.
M. Belhassen, F. Tubach, C. Hudry, M.-C. Woronoff, L. Levy-Bachelot, L. Lamezec,
E. Van Ganse, B. Fautrel. “Impact of non-persistence to subcutaneous TNF-Alpha inhibitors on medical resource utilization and costs